Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Farampator. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA3 known ✓ | P42263 | 1/20 | 1.00 |
| ▸ | GRIA4 known ✓ | P48058 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 18/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760125 | 1.00 | GRIA3 (1.00) | GRIA3GRIA4HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL5758316 | 0.98 | GRIA3 (0.97) | GRIA3GRIA4HPGDALDH1A1SMN1; SMN2 | |
| Cx-717 SCHEMBL243542 | 0.86 | GRIA3 (0.76) | GRIA3GRIA4HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL5757878 | 0.85 | GRIA3 (0.74) | GRIA3GRIA4HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL6575384 | 0.85 | GRIA3 (0.74) | GRIA3GRIA4HPGDALDH1A1TSHR | |
| SCHEMBL5759402 | 0.84 | GRIA3 (0.72) | GRIA3GRIA4HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL5791567 | 0.84 | GRIA3 (0.72) | GRIA3GRIA4HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL5755898 | 0.83 | GRIA3 (0.70) | GRIA3GRIA4HPGDALDH1A1RECQL | |
| SCHEMBL5758784 | 0.82 | GRIA3 (0.70) | GRIA3GRIA4HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL243412 | 0.82 | GRIA3 (0.70) | GRIA3GRIA4HPGDALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| EP-2558100-A1 | COMPOSITIONS AND METHODS FOR TREATING VISUAL DISORDERS | Allergan, Inc. (US) | 2013-02-20 | — | — | EP | claimed |
| WO-2011130411-A1 | COMPOSITIONS AND METHODS FOR TREATING VISUAL DISORDERS | ALLERGAN, INC. (US) | 2011-10-20 | — | — | WO | claimed |
| US-20110257186-A1 | COMPOSITIONS AND METHODS FOR TREATING VISUAL DISORDERS | ALLERGAN, INC. | 2011-10-20 | — | — | US | claimed |
| US-20060276462-A1 | Method of treating cognitive decline due to sleep deprivation and stress | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2006-12-07 | — | — | US | claimed |
| EP-1592464-A2 | METHOD OF TREATING COGNITIVE DECLINE DUE TO SLEEP DEPRIVATION AND STRESS | CORTEX PHARMACEUTICALS, INC. (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004062616-A2 | METHOD OF TREATING COGNITIVE DECLINE DUE TO SLEEP DEPRIVATION AND STRESS | CORTEX PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| EP-0960105-B1 | BENZOFURAZAN COMPOUNDS THAT ENHANCE AMPA RECEPTOR ACTIVITY | UNIV CALIFORNIA (US) | 2004-05-12 | — | — | EP | claimed |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | CORTEX PHARMACEUTICALS, INC. | 2002-05-09 | — | — | US | claimed |
| US-20020055498-A1 | Benzofurazan compounds for enhancing glutamatergic synaptic responses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-05-09 | — | — | US | claimed |
| US-6110935-A | A PROMOTER FOR N-METHYL-D-ASPARTIC ACID (NMDA) RECEPTORS, USEFUL FOR SUCH THERAPEUTIC PURPOSES AS FACILITATING THE LEARNING OF BEHAVIORS, TREATING SCHIZOPHRENIA, MEMORY IMPAIRMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-29 | — | — | US | claimed |
| EP-0960105-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | The Regents of the University of California (US) | 1999-12-01 | — | — | EP | claimed |
| WO-1998035950-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | claimed |
| US-20260071276-A1 | GPCR LATROPHILIN-3 AS BIOMARKER FOR DETECTING INCREASED RISK FOR MILD BRAIN INJURY AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF THE SAME | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12303549-B2 | Methods of treating or inhibiting onset of Huntington's disease | UNIVERSITY OF ROCHESTER (US) | 2025-05-20 | — | — | US | disclosed |
| US-6110935-A | A PROMOTER FOR N-METHYL-D-ASPARTIC ACID (NMDA) RECEPTORS, USEFUL FOR SUCH THERAPEUTIC PURPOSES AS FACILITATING THE LEARNING OF BEHAVIORS, TREATING SCHIZOPHRENIA, MEMORY IMPAIRMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0960105-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | The Regents of the University of California (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998035950-A1 | BENZOFURAZAN COMPOUNDS WHICH ENHANCE AMPA RECEPTOR ACTIVITY | CORTEX PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257186-A1 | COMPOSITIONS AND METHODS FOR TREATING VISUAL DISORDERS | CBR3, SCN7A, ADCY7 | GRIA3 172/4885GRIA4 229/4885HPGD 2606/4885 |
| US-20020055498-A1 | Benzofurazan compounds for enhancing glutamatergic synaptic responses | GRIN1, GABRE, GABRG1 | GRIA3 23/4885GRIA4 8/4885HPGD 1392/4885 |
| US-20260071276-A1 | GPCR LATROPHILIN-3 AS BIOMARKER FOR DETECTING INCREASED RISK FOR MILD BRAIN INJURY AND METHODS OF USE THEREOF FOR DIAGNOSIS AND TREATMENT OF THE SAME | GPR3, OPRL1, ADGRF1 | GRIA3 235/4885GRIA4 841/4885HPGD 3731/4885 |
| US-20020055508-A1 | Treating memory impairment; enhance excitatory synaptic activity in order to restore an imbalance between brain subregions, as in treatment of schizophrenia or schizophreniform behavior. | GRIN1, GABRE, GRM1 | GRIA3 11/4885GRIA4 4/4885HPGD 1707/4885 |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | GRIA3 26/4885GRIA4 22/4885HPGD 3070/4885 |
| US-20060276462-A1 | Method of treating cognitive decline due to sleep deprivation and stress | GRIN2A, GRIN1, GRIK5 | GRIA3 30/4885GRIA4 21/4885HPGD 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.